87 related articles for article (PubMed ID: 36414192)
1. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
Borghaei H; Ciuleanu TE; Lee JS; Pluzanski A; Caro RB; Gutierrez M; Ohe Y; Nishio M; Goldman J; Ready N; Spigel DR; Ramalingam SS; Paz-Ares LG; Gainor JF; Ahmed S; Reck M; Maio M; O'Byrne KJ; Memaj A; Nathan F; Tran P; Hellmann MD; Brahmer JR
Ann Oncol; 2023 Feb; 34(2):173-185. PubMed ID: 36414192
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.
Kato K; Doki Y; Chau I; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Makino T; Blum Murphy M; Amaya-Chanaga C; Patel A; Hu N; Matsumura Y; Kitagawa Y; Ajani J
Cancer Med; 2024 May; 13(9):e7235. PubMed ID: 38716626
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.
Melero I; Yau T; Kang YK; Kim TY; Santoro A; Sangro B; Kudo M; Hou MM; Matilla A; Tovoli F; Knox J; He AR; El-Rayes B; Acosta-Rivera M; Lim HY; Soleymani S; Yao J; Neely J; Tschaika M; Hsu C; El-Khoueiry AB
Ann Oncol; 2024 Jun; 35(6):537-548. PubMed ID: 38844309
[TBL] [Abstract][Full Text] [Related]
4. Real-world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non-small cell lung cancer.
Kaneko A; Kobayashi N; Miura K; Matsumoto H; Somekawa K; Hirose T; Kajita Y; Tanaka A; Teranishi S; Sairenji Y; Kawashima H; Yumoto K; Tsukahara T; Fukuda N; Nishihira R; Watanabe K; Horita N; Hara Y; Kudo M; Miyazawa N; Kaneko T
Thorac Cancer; 2024 May; 15(15):1208-1217. PubMed ID: 38602166
[TBL] [Abstract][Full Text] [Related]
5. A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma.
McKay RR; Leucht K; Xie W; Jegede O; Braun DA; Atkins MB; Grimm MO; Choueiri TK
Oncologist; 2024 Apr; 29(4):324-331. PubMed ID: 37950901
[TBL] [Abstract][Full Text] [Related]
6. Time-dependent efficacy analysis of first-line immunotherapies for advanced non-small cell lung cancer.
Hui W; Li W; Song R; Xin Y; Wu C; Gao Z; Zhang M; Wu H; Zhu M; Cai Y
BMC Cancer; 2024 Jun; 24(1):684. PubMed ID: 38840087
[TBL] [Abstract][Full Text] [Related]
7. PD-L1-negative Non-small-cell Lung Cancer Treated with Nivolumab Plus Ipilimumab during Maintenance Hemodialysis Results in Rapid Initial Progression Followed by a Long-lasting Response.
Yano S; Uematsu S; Kunimune N; Harima T; Yoshida Y; Takahashi S; Ito M; Sakamoto H; Nishizaka Y
Intern Med; 2024 Apr; 63(7):985-988. PubMed ID: 37558475
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032).
Callahan M; Amin A; Kaye FJ; Morse MA; Taylor MH; Peltola KJ; Sharma P; O'Reilly EM; Meadows Shropshire S; O'Brien S; Tschaika M; Le DT
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38316517
[TBL] [Abstract][Full Text] [Related]
9. First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Imai H; Kijima T; Azuma K; Kishi K; Saito H; Yamaguchi T; Tanizaki J; Yoneshima Y; Fujita K; Watanabe S; Kitazono S; Fukuhara T; Hataji O; Toi Y; Mizutani H; Hamakawa Y; Maemondo M; Ohsugi T; Suzuki K; Horinouchi H; Ohe Y
Jpn J Clin Oncol; 2024 Apr; 54(4):452-462. PubMed ID: 38271158
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis.
Cui S; Sun X; Gao J
Expert Rev Anticancer Ther; 2024 May; 24(5):283-291. PubMed ID: 38532600
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040.
El-Khoueiry AB; Trojan J; Meyer T; Yau T; Melero I; Kudo M; Hsu C; Kim TY; Choo SP; Kang YK; Yeo W; Chopra A; Soleymani S; Yao J; Neely J; Tschaika M; Welling TH; Sangro B
Ann Oncol; 2024 Apr; 35(4):381-391. PubMed ID: 38151184
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer.
Zhou Y; Zhang Y; Guo G; Cai X; Yu H; Cai Y; Zhang B; Hong S; Zhang L
Clin Transl Med; 2020 Jan; 10(1):107-115. PubMed ID: 32508007
[TBL] [Abstract][Full Text] [Related]
13. US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer.
Akinboro O; Drezner N; Amatya A; Runyan J; Fourie-Zirkelbach J; Zhao M; Bi Y; Korsah K; Mixter B; Tang S; Larkins E; Pazdur R; Beaver JA; Singh H
J Clin Oncol; 2023 Jun; 41(17):3249-3259. PubMed ID: 37141544
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.
Dumoulin DW; Douma LH; Hofman MM; van der Noort V; Cornelissen R; de Gooijer CJ; Burgers JA; Aerts JGJV
Lung Cancer; 2024 Jan; 187():107440. PubMed ID: 38104353
[TBL] [Abstract][Full Text] [Related]
15. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer.
Feldman H; Sepesi B; Leung CH; Lin H; Weissferdt A; Pataer A; William WN; Walsh GL; Rice DC; Roth JA; Mehran RJ; Hofstetter WL; Antonoff MB; Rajaram R; Gibbons DL; Lee JJ; Heymach JV; Vaporciyan AA; Swisher SG; Cascone T
J Thorac Cardiovasc Surg; 2024 Apr; 167(4):1444-1453.e4. PubMed ID: 37816395
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab.
Mouri A; Watanabe S; Tokito T; Nagai Y; Saida Y; Imai H; Yamaguchi O; Kobayashi K; Kaira K; Kagamu H
Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611087
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia.
Patel SP; Othus M; Chae YK; Dennis MJ; Gordon S; Mutch D; Samlowski W; Robinson WRR; Sharon E; Ryan C; Lopez G; Plets M; Blanke C; Kurzrock R
Clin Cancer Res; 2024 Jan; 30(1):33-38. PubMed ID: 37882676
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study.
Karadurmus N; Kaplan MA; Sendur MAN; Urun Y; Demirci U; Karaca SB; Goktas Aydin S; Aykan MB; Bilici A; Sezer A; Yilmaz U; Abali H; Yumuk PF; Degirmencioglu S; Demirkazik A; Paydas S; Mirili C; Turna H; Kargi A; Ozdogan M; Guven DC; Ozguroglu M; Kilickap S
Curr Med Res Opin; 2024 May; ():1-21. PubMed ID: 38809230
[TBL] [Abstract][Full Text] [Related]
19. Use of Different Anti-PD-1 Checkpoint Combination Strategies for First-Line Advanced NSCLC Treatment-The Experience of Ion Chiricuță Oncology Institute.
Preda AC; Ciuleanu TE; Todor N; Vlad C; Iancu DI; Mocan C; Bandi-Vasilica M; Albu F; Todor-Bondei IM; Hapca MC; Kubelac MP; Kubelac-Varro AD
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893141
[TBL] [Abstract][Full Text] [Related]
20. Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.
Parra ER; Zhang J; Duose DY; Gonzalez-Kozlova E; Redman MW; Chen H; Manyam GC; Kumar G; Zhang J; Song X; Lazcano R; Marques-Piubelli ML; Laberiano-Fernandez C; Rojas F; Zhang B; Taing L; Jhaveri A; Geisberg J; Altreuter J; Michor F; Provencher J; Yu J; Cerami E; Moravec R; Kannan K; Luthra R; Alatrash G; Huang HH; Xie H; Patel M; Nie K; Harris J; Argueta K; Lindsay J; Biswas R; Van Nostrand S; Kim-Schulze S; Gray JE; Herbst RS; Wistuba II; Gettinger S; Kelly K; Bazhenova L; Gnjatic S; Lee JJ; Zhang J; Haymaker C
Clin Cancer Res; 2024 Apr; 30(8):1655-1668. PubMed ID: 38277235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
